Search Result

Isoforms Recommended:	Tyk2

Results for "

TYK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ack1 (1) AMPK (2) Apoptosis (3) Cathepsin (1) Cytochrome P450 (1) Drug Isomer (1) FGFR (1) FLT3 (1) GSK-3 (1) HBV (1) HCV (1) HIV (2) IFNAR (6) IKK (1) Interleukin Related (4) Isotope-Labeled Compounds (4) JAK (100) JNK (1) Ligands for Target Protein for PROTAC (1) LRRK2 (2) p38 MAPK (1) Phosphodiesterase (PDE) (1) PKC (1) PROTACs (2) Small Interfering RNA (siRNA) (3) STAT (6) Syk (4) VEGFR (1)
By Research Areas:	Cancer (39) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (61) Metabolic Disease (1) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

106

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144031S

Tyk2-IN-8	Isotope-Labeled Compounds JAK	Inflammation/Immunology
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-158340

TYK2 ligand 1	JAK Ligands for Target Protein for PROTAC	Cancer
TYK2 ligand 1 is a *TYK2* ligand in the synthesis of PROTAC-based TYK2 degrader (CPD-155, HY-158142) .

HY-RS15300

TYK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TYK2 Human Pre-designed siRNA Set A contains three designed siRNAs for TYK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TYK2 Human Pre-designed siRNA Set A TYK2 Human Pre-designed siRNA Set A

HY-RS15302

Tyk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tyk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tyk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tyk2 Rat Pre-designed siRNA Set A Tyk2 Rat Pre-designed siRNA Set A

HY-RS15301

Tyk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tyk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tyk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tyk2 Mouse Pre-designed siRNA Set A Tyk2 Mouse Pre-designed siRNA Set A

HY-163303

Tyk2-IN-15	JAK	Inflammation/Immunology
Tyk2-in-15 (Compound 97) is a selective tyrosine kinase 2 (Tyk2) inhibitor with IC₅₀ value ≤ 10 nM for Tyk2-JH2. Tyk2-IN-15 can be used in the study of inflammatory or autoimmune diseases .

HY-163304

Tyk2-IN-16	JAK	Cancer
Tyk2-IN-16 is a selective and potent *TYK2* inhibitor with an IC₅₀ of <10 nM for TYK2-JH2. Tyk2-IN-16 inhibits pSTAT4 with an IC₅₀ of <10 nM in NK92 cells (WO2023220046A1; compound 184) .

HY-163313S

Tyk2-IN-19-d6	Isotope-Labeled Compounds	Inflammation/Immunology
Tyk2-IN-19-d6 (compound 15) is the deuterium labeled Tyk2-IN-19 (HY-163313) .

HY-168269

Tyk2-IN-20	JAK	Cancer
Tyk2-IN-20 (Example 289) is a potent *Tyk2* inhibitor with an IC₅₀ of <5 nM. Tyk2-IN-20 als inhibits JAK1, *JAK2, and JAK3* with IIC₅₀ values of <100 nM. Tyk2-IN-20 can be used for the study of inflammatory diseases .

HY-18709

Tyk2-IN-3	JAK	Inflammation/Immunology
Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC₅₀ of 485 nM.

HY-163305

Tyk2-IN-17	JAK	Inflammation/Immunology
Tyk2-IN-17 (compound 185) is a potent TYK2 inhibitor .

HY-161683

Tyk2-IN-19	JAK	Neurological Disease
Tyk2-IN-19 (compound 1) is an orally active and blood-brain barrier (BBB) permeable *Tyk2* inhibitor. Tyk2-IN-19 can be used for study of neurodegenerative diseases .

HY-144032

Tyk2-IN-9	JAK	Inflammation/Immunology
Tyk2-IN-9 (Compound 26) is a selective *Tyk-2* inhibitor with IC₅₀s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease .

HY-144087

TYK2-IN-11	JAK	Inflammation/Immunology
TYK2-IN-11 (Compound 5B) is a selective *Tyk-2* inhibitor with IC₅₀s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease .

HY-111745

Tyk2-IN-5	JAK	Inflammation/Immunology
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the *JH2* structural domain. Tyk2-IN-5 shows a K_i value of 0.086 nM for **Tyk2 JH2 and an IC₅₀** value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .

HY-101762

TyK2-IN-2	JAK Phosphodiesterase (PDE)	Inflammation/Immunology
TyK2-IN-2 (Compoud 18) is a potent and selective *TYK2* inhibitor with IC₅₀s of 7 nM, 0.1 μM and 0.05 μM for **TYK2 JH2, IL-23 and IFNα*, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4)* with an IC₅₀ of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .

HY-126242S

Tyk2-IN-7	JAK	Inflammation/Immunology
Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-168339

Tyk2-IN-22	JAK	Inflammation/Immunology
Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

HY-158692

Tyk2-IN-18	JAK	Cancer
Tyk2-IN-18 (compound 86) is a potent tyrosine kinase 2 (Tyk2) inhibitor. Tyk2-IN-18 inhibits JAK2-JH2, with an IC₅₀ of ＜10 nM ^[2].

HY-169984S

Tyk2-IN-22-d3	Isotope-Labeled Compounds STAT JAK	Inflammation/Immunology
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation ^[2].

HY-150720

TYK2-IN-12	JAK IFNAR	Inflammation/Immunology
TYK2-IN-12 (compound 30) is an orally active, potent and selective *TYK2* (tyrosine kinase 2) inhibitor, with a K_i of 0.51 nM. TYK2-IN-12 inhibits IL-12 induced IFNγ, with IC₅₀ values of 2.7 and 7.0 μM in human and mouse whole blood, respectively. TYK2-IN-12 can be used for psoriasis research .

HY-163312S

Tyk2-IN-18-d5	JAK	Inflammation/Immunology
Tyk2-IN-18-d5 (Compound 13) is the deuterated *TYK2* inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .

HY-163314S

Tyk2-IN-18-d3	JAK Interleukin Related IFNAR	Inflammation/Immunology
Tyk2-IN-18-d3 (Compound 18) is a *Tyk2* inhibitor with an IC₅₀ value of < 30 nM for both IL-23 and IFNα. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .

HY-169986S

TyK2-IN-21-d3	JAK	Inflammation/Immunology
TyK2-IN-21-d3 (Compound 3c) is the orally active prodrug of the tyrosine kinase 2. TyK2-IN-21-d3 exhibits good chemical stability in aqueous system under different pHs. TyK2-IN-21-d3 alleviates the effect of gastric acid changes on drug absorption and improve the drug bioavailability in rat model .

HY-138317

Tyk2-IN-10	JAK	Cancer
Tyk2-IN-10 (compound 17.5) is a tyrosine kinase 2-mediated signaling inhibitor involved in inflammation regulation .

HY-149892S

TYK2 JH2-IN-1-d3	JAK	Cancer
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

HY-158142

*PROTAC TYK2* degrader-1**	PROTACs JAK	Cancer
PROTAC TYK2 degrader-1 (CPD-155) is a PROTAC targeting degrader to *TYK2* with D_max >60%. (Structure Note: PINK, TYK2 ligand 1 (HY-158340); Blue, VHL ligand Thalidomide (HY-14658); Black, linker)

HY-152227

*PROTAC TYK2* degradation agent1**	PROTACs JAK	Inflammation/Immunology
PROTAC TYK2 degradation agent1 is a potent and subtype-selective *TYK2* degrader. PROTAC TYK2 degradation agent1 has TYK2 degradation activity with DC₅₀ value of 14 nM. PROTAC TYK2 degradation agent1 can be used for the research of autoimmune disease .

HY-143884

*JAK2/TYK2-IN-1*	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective *TYK2* inhibitor with IC₅₀ values of 9 and 157 nM for *TYK2* and *JAK2, respectively. JAK2/TYK2*-IN-2 has anti-inflammatory activity .

HY-161019

*JAK1/TYK2-IN-4*	JAK	Inflammation/Immunology
JAK1/TYK2-IN-4 is a dual inhibitor of JAK and TYK2, with IC₅₀s of 39 nM and 21 nM, respectively. JAK1/TYK2-IN-4 has oral bioavailability .

HY-145336

*JAK1/TYK2-IN-1*	JAK	Cancer
JAK1/TYK2-IN-1 is a dual inhibitor of *TYK2* and JAK1 (IC₅₀ = 29 and 41 nM respectively).

HY-143885

*JAK1/TYK2-IN-3*	JAK	Inflammation/Immunology
JAK1/TYK2-IN-3 is a potent, selective and orally active dual *TYK2/JAK1* inhibitor with IC₅₀ values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to *JAK2* (IC₅₀=140 nM) and JAK3 (IC₅₀=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related *TYK2/JAK1*-regulated genes, as well as the formation of Th1, Th2, and Th17 cells .

HY-153103

*LRRK2/NUAK1/TYK2-IN-1*	LRRK2 JAK AMPK	Inflammation/Immunology
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), *TYK2* and NUAK1, with IC₅₀ values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research .

HY-120469

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK	Inflammation/Immunology
GDC-046 is a potent, selective, and orally bioavailable *TYK2* inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .

HY-156409

ABBV-712	JAK	Inflammation/Immunology
ABBV-712 is a selective inhibitor of Tyrosine kinase 2 (TYK2), with IC50 of 0.195 μM, that play important role in autoimmune diseases .

HY-16640

TCJL37	JAK	Inflammation/Immunology
TCJL37 is a potent, selective, and orally bioavailable *TYK2* inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .

HY-150096

Zasocitinib NDI-034858; TAK-279	JAK	Inflammation/Immunology
Zasocitinib (NDI-034858) is a *TYK2* inhibitor, target **TYK2 JH2** domain with binding constant K_d of <200 pM .

HY-153058

LRRK2-IN-8	LRRK2 JAK AMPK	Neurological Disease Cancer
LRRK2-IN-8 is a *LRRK2* inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC₅₀s lower than 10 nM, and inhibits *TYK2* and NUAK1 with IC₅₀s of 10-100 nM .

HY-152080

TUL01101	JAK	Inflammation/Immunology
TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis .

HY-131968

BMS-986202	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active *Tyk2* inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-19631B

Ilginatinib hydrochloride 1 Publications Verification NS-018 hydrochloride	JAK	Cancer
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631A

Ilginatinib 1 Publications Verification NS-018	JAK	Cancer
Ilginatinib (NS-018) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631

Ilginatinib maleate 1 Publications Verification NS-018 maleate	JAK	Cancer
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-160144S

Lomedeucitinib BMS-986322	Isotope-Labeled Compounds JAK IFNAR	Inflammation/Immunology
Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC₅₀=0.047 μM) production downstream of *IL-12/TYK2*. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus ^[2] .

HY-117287

Deucravacitinib Maximum Cited Publications 18 Publications Verification BMS-986165	JAK Interleukin Related IFNAR	Inflammation/Immunology
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric *TYK2* inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis ^[2].

HY-160144S2

(rac)-Lomedeucitinib (rac)-BMS-986322	Drug Isomer	Others
(rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus ^[2] .

HY-15999A

Cerdulatinib hydrochloride 5+ Cited Publications PRT062070 hydrochloride; PRT2070 hydrochloride	Syk JAK	Cancer
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC₅₀s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and *Tyk2, JAK1*, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies ^[2].

HY-18316

RO495	JAK	Inflammation/Immunology
RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2 kinase) .

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722A

NVP-BSK805 dihydrochloride 3 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

524 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 524 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Compare	Product Name	Species	Source

HY-P702722

	TYK2 Protein, Human (Biotinylated, sf9, His, Flag, Avi) TYK2; tyrosine kinase 2; non-receptor tyrosine-protein kinase TYK2; JTK1	Human	Sf9 insect cells
	TYK2 Protein, Human (Biotinylated, sf9, His, Flag, Avi) is the recombinant human-derived TYK2, expressed by Sf9 insect cells , with His, Avi, Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-131968

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-160144S

Lomedeucitinib
Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC₅₀=0.047 μM) production downstream of *IL-12/TYK2*. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus ^[2] .

HY-117287

Deucravacitinib

15+ Cited Publications

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis ^[2].

HY-163313S

Tyk2-IN-19-d6
Tyk2-IN-19-d6 (compound 15) is the deuterium labeled Tyk2-IN-19 (HY-163313) .

HY-169984S

Tyk2-IN-22-d3
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation ^[2].

HY-163312S

Tyk2-IN-18-d5
Tyk2-IN-18-d5 (Compound 13) is the deuterated *TYK2* inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .

HY-163314S

Tyk2-IN-18-d3
Tyk2-IN-18-d3 (Compound 18) is a *Tyk2* inhibitor with an IC₅₀ value of < 30 nM for both IL-23 and IFNα. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .

HY-149892S

TYK2 JH2-IN-1-d3
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

HY-160144S2

(rac)-Lomedeucitinib
(rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus ^[2] .

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: